Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Caprion Pharma teams with Berlex
February 2006
SHARING OPTIONS:

MONTREALóCaprion Pharmaceuticals Inc. recently announced a research collaboration with Berlex Inc., a U.S. affiliate of Schering AG, Germany. The collaboration will use Caprion's CellCarta proteomics platform to support biomarker discovery. Caprion will identify pharmacodynamic biomarkers in plasma resulting from the administration of Berlex compounds in pre-clinical development.
 
"Caprion is looking forward to working with Berlex on their preclinical therapeutic candidates," says Dr. Daniel Chelsky, CSO at Caprion. "We believe Caprion's capabilities in the discovery of protein biomarkers will significantly impact our partner's development efforts."
 
Caprion's proprietary proteomics platform profiles the expression and identity of proteins detected in tissues and blood plasma. Caprion is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies.†

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.